Authors: Y Rhee M Kang Y Min D Byun Y Chung C Ahn K Baek J Mok D Kim D Kim H Kim Y Kim S Myoung D Kim SK Lim
Publish Date: 2006/09/26
Volume: 17, Issue: 12, Pages: 1801-1807
Abstract
A total of 217 postmenopausal women with osteoporosis were enrolled 199 patients were randomly assigned to one of two treatment groups Maxmarvil group or alfacalcidol group None of the patients were vitaminDdeficient as assessed by serum 25hydroxyvitamin D 25OHD nor had they received any drugs affecting bone metabolism before enrollment Bone mineral densities BMD of L1–L4 and the femur were measured by dualenergy Xray absorptiometry DXA at the initial assessment and after 6 months of treatment Serum biochemical assays including serum calcium 24h urinary calcium excretion and bone turnover markers both bonespecific alkaline phosphatase bsALP and urine Ntelopeptide NTx were performed at the baseline and after 3 and 6 months of treatmentIn the Maxmarvil group the BMD of the lumbar spine increased up to 242±05 from the baseline after 6 months p005 On the other hand the change in BMD in the alfacalcidol group was 028±05 after 6 months There was no significant difference in femoral BMD between the two groups The levels of bsALP and NTx were significantly lower in the Maxmarvil group than in the alfacalcidol group −2204±39 vs −1142±28 p005 and −2546±52 vs 124±62 p0001 respectively Interestingly there was a significantly smaller amount of 24h urinary calcium in the Maxmarvil group p005
Keywords: